The most common liver cancer is hepatocellular carcinoma.Other liver malignancies include hemangioendotheliomas, sarcomas, hepatoblastoma, cholangiocarcinoma, lymphoma, angiosarcoma, and hemangiosarcoma.Furthermore, the liver is frequently the site of metastases from tumors of the gastrointestinal tract (colon, stomach, appendiceal carcinoids), as well as malignant tumors of the breast, ovary, lung, kidney, and prostate. Symptoms of hepatocellular carcinoma include abdominal pain, a palpable abdominal mass, vomiting, anemia, back pain, jaundice, pruritus, weight loss, and fever.
The symptoms of cholangiocarcinoma are essentially jaundice, weight loss, hepatomegaly, and abdominal pain. Available treatments for malignant liver cancer include surgery, chemotherapy, immunotherapy, photodynamic therapy, hyperthermia, radiotherapy, and radiosurgery.
Surgery involves partial or total liver resection, possibly with a donor transplant.Alternatively, tumor ablation can be performed using radiofrequency, cryotherapy, or chemotherapy.
Treatment with radiotherapy and/or neoadjuvant chemotherapy may be considered. The following indicator has been defined: “Mortality within 30 days of surgery for malignant liver cancer.”
This indicator assesses the surgical risk of patients diagnosed with malignant liver cancer who undergo surgery in terms of mortality during surgery, during the postoperative hospital stay, or within 30 days of surgery.
The indicator measures death within 30 days of surgery as the outcome and considers the hospitalization as the exposure. The indicator’s value may differ between regions and facilities due to varying quality of care, but it may also be attributable to the heterogeneous distribution of various risk factors, such as patient age, gender, and comorbidities.
Your doctor will address your concerns and guide you in making an informed decision about the treatment plan to follow.Contact him or her for all the information you need for your health needs.
Indicators 
